# Zbyšek Pavelek

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/zbysek-pavelek/

## Facts

| Field | Value |
| --- | --- |
| Citations | 412 |
| Field | Multiple Sclerosis Research Studies |
| h-index | 12 |
| i10-index | 13 |
| Last Known Institution | Charles University |
| OpenAlex ID | https://openalex.org/A5010009633 |
| ORCID iD | 0000-0002-1772-8781 |
| Works | 73 |

## Researcher papers

- [Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review](https://scholariq.org/papers/treatment-of-behavioral-and-psychological-symptoms-of-dementias-with/)
- [Deep Learning for Accelerometric Data Assessment and Ataxic Gait Monitoring](https://scholariq.org/papers/deep-learning-for-accelerometric-data-assessment-and-ataxic-gait-monitoring/)
- [Acupuncture in migraine prophylaxis in Czech patients: an open-label randomized controlled trial](https://scholariq.org/papers/acupuncture-in-migraine-prophylaxis-in-czech-patients-an-open-label-randomized/)
- [The role of the immune system and the biomarker CD3 + CD4 + CD45RA−CD62L− in the pathophysiology of migraine](https://scholariq.org/papers/the-role-of-the-immune-system-and-the-biomarker-cd3-cd4-cd45ra-cd62l-in-the/)
- [Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome](https://scholariq.org/papers/proteomic-analysis-of-cerebrospinal-fluid-for-relapsing-remitting-multiple/)
- [Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries](https://scholariq.org/papers/does-initial-high-efficacy-therapy-in-multiple-sclerosis-surpass-escalation/)
- [The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer’s Disease Patients and Its Consequence to Oxidative Stress Biomarkers](https://scholariq.org/papers/the-concentration-of-memantine-in-the-cerebrospinal-fluid-of-alzheimer-s-disease/)
- [The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021](https://scholariq.org/papers/the-czech-national-ms-registry-remus-data-trends-in-multiple-sclerosis-patients/)
- [The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis](https://scholariq.org/papers/the-benefits-and-risks-of-switching-from-fingolimod-to-siponimod-for-the/)
- [In Silico Studies of Potential Selective Inhibitors of Thymidylate Kinase from Variola virus](https://scholariq.org/papers/in-silico-studies-of-potential-selective-inhibitors-of-thymidylate-kinase-from/)

## Researcher topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

## Researcher university

- [Charles University](https://scholariq.org/institutions/charles-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.